SEARCH

SEARCH BY CITATION

References

  • Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G et al . (1999). Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90, 113.
  • Desmond DW, Moroney JT, Sano M & Stern Y (2002). Incidence of dementia after ischemic stroke: results of a longitudinal study. Stroke 33, 22542260.
  • Dumont M, Lalonde R, Ghersi-Egea JF, Fukuchi K & Strazielle C (2005). Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP. J Neural Transm; DOI: DOI: 10.1007/s00702-005-0373-6.
  • Furukawa K, Barger SW, Blalock EM & Mattson MP (1996). Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature 379, 7478.
  • Glenner GG & Wong CW (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885890.
  • Grote J, Laue O, Eiring P & Wehler M (1996). Evaluation of brain tissue O2 supply based on results of PO2 measurements with needle and surface microelectrodes. J Auton Nerv Syst 57, 168172.
  • Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD et al . (2005). Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1, 401408.
  • Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL et al . (1992). Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322325.
  • Hall ED, Oostveen JA, Dunn E & Carter DB (1995). Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp Neurol 135, 1727.
  • Jendroska K, Hoffmann OM & Patt S (1997). Amyloid beta peptide and precursor protein (APP) in mild and severe brain ischemia. Ann NY Acad Sci 826, 401405.
  • Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S & Malinow R (2003). APP processing and synaptic function. Neuron 37, 925937.
  • Kokmen E, Whisnant JP, O'Fallon WM, Chu CP & Beard CM (1996). Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960–84). Neurology 46, 154159.
  • LaFerla FM (2002). Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3, 862872.
  • Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M et al . (2002). A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A 99, 46974702.
  • Lesne S, Ali C, Gabriel C, Croci N, MacKenzie ET, Glabe CG et al . (2005). NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci 25, 93679377.
  • Li D, Marks JD, Schumacker PT, Young RM & Brorson JR (2005). Physiological hypoxia promotes survival of cultured cortical neurons. Eur J Neurosci 22, 13191326.
  • Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P et al . (2001). Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4, 231232.
  • Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves D C, Vincent B et al . (2005). Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 46, 541554.
  • Plant LD, Boyle JP, Smith IF, Peers C & Pearson HA (2003). The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 23, 55315535.
  • Plant LD, Webster NJ, Boyle JP, Ramsden M, Freir DB, Peers C & Pearson HA (2005). Amyloid beta peptide as a physiological modulator of neuronal ‘A’-type K+ current. Neurobiol Aging In Press
  • Ramsden M, Plant LD, Webster NJ, Vaughan PF, Henderson Z & Pearson HA (2001). Differential effects of unaggregated and aggregated amyloid beta protein (1–40) on K+ channel currents in primary cultures of rat cerebellar granule and cortical neurones. J Neurochem 79, 699712.
  • Ramsden M, Henderson Z & Pearson HA (2002). Modulation of Ca2+ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1–40) is dependent on solubility status. Brain Res 956, 254261.
  • Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M et al . (2005). High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem 280, 3295732967.
  • Selkoe DJ & Schenk D (2003). Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43, 545584.
  • Shi J, Yang SH, Stubley L, Day AL & Simpkins JW (2000). Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model. Brain Res 853, 14.
  • Smith IF, Boyle JP, Green KN, Pearson HA & Peers C (2004). Hypoxic remodeling of Ca2+ mobilization in type I cortical astrocytes: involvement of ROS and pro-amyloidogenic APP processing. J Neurochem 88, 869877.
  • Smith IF, Plant LD, Boyle JP, Skinner RA, Pearson HA & Peers C (2003). Chronic hypoxia potentiates capacitative Ca2+ entry in type I cortical astrocytes. J Neurochem 85, 11091116.
  • Smith RP, Higuchi DA & Broze GJ Jr (1990). Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 248, 11261128.
  • Soucek T, Cumming R, Dargusch R, Maher P & Schubert D (2003). The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 39, 4356.
  • Steinbach JP, Muller U, Leist M, Li ZW, Nicotera P & Aguzzi A (1998). Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice. Cell Death Differ 5, 858866.
  • Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M et al . (1997). Amyloid beta protein 42 (43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 148, 4145.
  • Taylor SC, Batten TF & Peers C (1999). Hypoxic enhancement of quantal catecholamine secretion. Evidence for the involvement of amyloid beta-peptides. J Biol Chem 274, 3121731222.
  • Turner AJ, Fisk L & Nalivaeva NN (2004). Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann N Y Acad Sci 1035, 120.
  • Vardy ER, Catto AJ & Hooper NM (2005). Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 11, 464472.
  • Von Koch CS, Zheng H, Chen H, Trumbauer M, Thinakaran G, Van der Ploeg LH, Price DL & Sisodia SS (1997). Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging 18, 661669.
  • Webster NJ, Ramsden M, Boyle JP, Pearson H & Peers C (2006). Amyloid peptides mediate hypoxic increase of L-type Ca2+ channels in central neurones. Neurobiol Aging 27, 439445.
  • Wong CW, Quaranta V & Glenner GG (1985). Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci U S A 82, 87298732.
  • Yu SP (2003). Regulation and critical role of potassium homeostasis in apoptosis. Prog Neurobiol 70, 363386.